参苓白术散联合沙美特罗治疗COPD的临床疗效分析

目的：探讨参苓白术散结合沙美特罗治疗对慢性阻塞性肺疾病（COPD）的临床疗效。方法：采用前瞻性随机对照设计。将93例COPD患者随机均分为三组（称为A、B、C组），A组给予中药参苓白术散口服和沙美特罗喷雾剂吸入治疗，B组给予中药参苓白术散颗粒剂口服治疗，C组给予沙美特罗喷雾剂吸入治疗，治疗疗程3个月，观察治疗前后三组患者的临床症状和体征、中医症状评分以及肺功能包括FEV1、FVC和PEF变化情况。结果：治疗3个月后，给予中药参苓白术散剂口服和沙美特罗喷雾剂吸入治疗的A组患者临床症状和体征、中医症状评分以及肺功能较治疗前明显改善，FEV1和FVC分别提高了0-3L和0-37L，PEF也增加了44L／min，并且这两种药物联合治疗疗效也明显优于B、c组（P〈0．05）。结论：参苓白术散结合沙关特罗治疗能明显改善COPD患者临床表现和肺功能。

Clinical Therapeutic Effect Analysis of the Treatment of COPD Combined Shenlingbaizhu Powder with Salmeterol

Objective： To investigate clinical therapeutic effect of chronic obstructive pulmonary disease （COPD） with Shenlingbaizhu powder combined with salmeterol. Methods： With a prospective randomized controlled design, ninety three COPD patients were randomly divided into three groups （i.e： A, B, C group）, group A patients take the traditional Chinese medicine Shenlingbaizhu powder orally combined with inhaled salmeterol treatment, group B patients were given Shenlingbaizhu powder for oral administration, and group C patients inhal salmeterol and these treatments take three months. Comparison of before and after treatment, three groups of clinical features, traditional Chinese medicine （TCM） symptoms and pulmonary function including FEVI, FVC and PEF have improved greatly. Results： After three months of treatment, the clinical features, traditional Chinese medicine （TCM） symptoms, pulmonary function were significantly improved in Group A. EV1 and FVC have improved and arrived at 0.3L and 0.37L, respectively, and PEF has increased to 44L/min. Furthermore, these two drugs in combination therapy in group A showed significantly better effect than group B and C （P〈0.05）. Conclusions： The treatment combined Shenlingbaizhu powder with salmeterol can significantly improve the clinical manifestations and pulmonary function of COPD patients.